BioCentury
ARTICLE | Cover Story

Inositol insulin insight

January 6, 2011 8:00 AM UTC

A lack of druggable targets in the insulin-Akt pathway has made increasing insulin signaling an uphill struggle for metabolic disease companies. Indeed, there are no approved drugs that directly modulate Akt or other intracellular components of the insulin response. Now, a team from

The Johns Hopkins Universityhas found that an inositol-derived signaling molecule called IP7 inhibits Akt as well as glucose utilization, thus opening up a new path for modulating insulin signaling.1...